


Modulating type 1 Interferon may expand treatment options for COVID-19

August 8 2023



Mx1 is more highly localized to viral foci in untreated SARS-CoV-2-infected RMs and IFNmod treatment decreases lung pathology. Representative staining

for (a) Mx1 and SARS-CoV-2 vRNA in lungs of untreated and IFNmod-treated RMs necropsied at 2 dpi. Right column contains zoomed-in images of black box regions in center column. (b) Scores for individual parameters of lung pathology, total lung pathology scores, and average pathology scores per lung lobe of RMs necropsied at 4 dpi (n=3 RMs per treatment group) and 7 dpi (n=3 RMs per treatment group) respectively. Untreated animals are depicted in red and IFNmod treated animals are depicted in blue. Black lines represent the median score of animals from each respective treatment group. Statistical analyses were performed using non-parametric Mann-Whitney tests. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value

Citation: Modulating type 1 Interferon may expand treatment options for COVID-19 (2023, August 8) retrieved 2 May 2024 from <https://medicalxpress.com/news/2023-08-modulating-interferon-treatment-options-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.